Compounding HRT Solutions for Libido and Sexual Wellness Patients

According to NIH MedlinePlus and NAMS (The Menopause Society), low sexual desire may present as a persistent or recurrent reduction in interest in sexual activity, including fewer spontaneous sexual thoughts, diminished responsiveness to sexual cues, reduced motivation to initiate intimacy, and a growing sense of emotional or physical distance from a partner. NAMS notes that this pattern may reflect hypoactive sexual desire disorder (HSDD) when it causes marked personal distress, and that hormonal changes — including declining estrogen and androgen levels — may contribute to reduced desire in women at midlife and beyond. Patients experiencing significant distress related to changes in sexual desire should seek evaluation from a qualified clinician; a sudden or marked change in desire alongside other symptoms such as fatigue, mood changes, or pelvic pain may indicate an underlying medical condition requiring assessment.

According to NIH MedlinePlus and ACOG, difficulty achieving orgasm — clinically referred to as female orgasmic disorder when persistent and distressing — may present as a delay, infrequency, or absence of orgasm following adequate sexual stimulation. ACOG notes that this symptom may have physiological contributors including reduced genital blood flow, hormonal changes, neurological factors, or pelvic floor dysfunction, as well as psychological and relational contributors. Patients experiencing persistent difficulty with orgasm alongside pelvic pain, numbness, or other neurological symptoms should seek evaluation from a qualified clinician; such presentations may indicate conditions requiring further medical assessment.

According to NIH MedlinePlus and ACOG, pain during intercourse (dyspareunia) may present as burning, stinging, sharp, or aching sensations at the vaginal entrance or deep in the pelvis during penetration or thrusting. ACOG notes that common contributors include vaginal dryness, vulvovaginal atrophy related to estrogen decline, pelvic floor dysfunction, infections, and psychological factors such as anxiety that may amplify the pain experience. Patients experiencing pain with intercourse should seek evaluation from a qualified clinician; new or worsening pelvic pain — particularly when accompanied by bleeding, discharge, or fever — may indicate a condition requiring prompt medical attention.

According to NIH MedlinePlus and the American Urological Association (AUA), erectile dysfunction may present as a persistent difficulty achieving or maintaining an erection sufficient for satisfactory sexual activity, including reduced firmness, inability to sustain an erection through intercourse, absent or infrequent morning erections, and delayed rigidity onset. The AUA notes that erectile dysfunction may reflect underlying vascular, neurological, hormonal, or psychological contributors, and that cardiovascular risk factors are frequently associated with this condition. Patients experiencing erectile dysfunction should seek evaluation from a qualified clinician; sudden onset erectile dysfunction accompanied by chest pain, shortness of breath, or other cardiovascular symptoms may indicate a condition requiring urgent medical attention.

According to the FDA-approved prescribing information for AndroGel, AndroGel is a topical testosterone gel indicated for testosterone replacement therapy in adult males with a documented condition of hypogonadism (primary or hypogonadotropic). The labeling describes that AndroGel delivers testosterone transdermally to raise serum testosterone concentrations toward the normal range. Per the labeling, AndroGel may cause skin irritation at the application site, and skin-to-skin transfer to others — including women and children — may occur if precautions are not taken; the labeling includes a boxed warning regarding this secondary exposure risk. Per the labeling, virilization has been reported in female partners and children with secondary exposure. Any compounded preparation involving testosterone is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available testosterone products are separately regulated, and clinical decisions about their use belong with the prescribing clinician.

According to the FDA-approved prescribing information for Vyleesi, Vyleesi (bremelanotide) is a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The labeling describes that bremelanotide acts on central melanocortin receptors; its mechanism of action in HSDD is not fully understood. Per the labeling, Vyleesi may cause nausea, flushing, and transient increases in blood pressure and decreases in heart rate following subcutaneous injection; the labeling notes that blood pressure should be considered before use in patients with cardiovascular conditions, and that Vyleesi is self-administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than eight doses per month. Any compounded preparation involving bremelanotide is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Vyleesi is separately regulated, and clinical decisions about its use belong with the prescribing clinician.